Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
- PMID: 33148544
- PMCID: PMC7643520 (V体育2025版)
- DOI: "VSports手机版" 10.1136/esmoopen-2020-000796
Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide in women and men. In incidence, lung cancer ranks second, surpassed by breast cancer in women and prostate cancer in men VSports手机版. However, the historical differences in mortality and incidence rate between both sexes have changed in the last years. In the last decades, we have also witnessed an increased number of lung cancer in female never-smokers. These disparities have grown our interest in studying the impact of the gender and sex in the presentation of lung cancer. The aetiology is yet to be fully elucidated, but the data are clear so far: there is a growing divide between lung cancer presentation in women and men that will change our management and study of lung cancer. This article aims to review the sex and gender differences in lung cancer. .
Keywords: gender; lung cancer; sex V体育安卓版. .
© Author (s) (or their employer(s)) 2020 V体育ios版. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. .
VSports手机版 - Conflict of interest statement
Competing interests: NM: declare no competing interests. AF: personal fees from BMS, Roche, Pfizer, Astellas, during the conduct of the Study. SP: has received education grants, provided consultation, attended advisory boards, and/or provided lectures for: Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F VSports最新版本. Hoffmann-La Roche, Foundation Medicine, Illumina, Incyte, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics and Takeda, from whom she has received honoraria. AA: personal fees from BMS, Astrazeneca, Roche, Pfizer, MSD, Boehringer, during the conduct of the study.
References
-
- Carioli G, Bertuccio P, Boffetta P, et al. . European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol 2020;31:650–8. 10.1016/j.annonc.2020.02.009 - V体育官网入口 - DOI - PubMed
-
- NIH Annual report to the nation: cancer death rates continue to decline, 2020.
Publication types
- "V体育ios版" Actions
MeSH terms
- Actions (VSports)
- VSports - Actions
- VSports最新版本 - Actions
- "V体育官网入口" Actions
- "V体育官网" Actions
LinkOut - more resources
Full Text Sources
VSports app下载 - Medical
